To access the full text documents, please follow this link: http://hdl.handle.net/2445/148191

Neuroadaptive changes and behavioral effects after a sensitization regime of MDPV
Duart Castells, Leticia; López Arnau, Raúl; Buenrostro Jáuregui, Mario; Muñoz Villegas, Patricia del Carmen; Valverde, O.; Camarasa, J.; Pubill Sánchez, David; Escubedo Rafa, Elena
Universitat de Barcelona
3,4-methylenedioxypyrovalerone (MDPV) is a synthetic cathinone with cocaine-like properties. In a previous work, we exposed adolescent mice to MDPV, finding sensitization to cocaine effects, and a higher vulnerability to cocaine abuse in adulthood. Here we sought to determine if such MDPV schedule induces additional behavioral-neuronal changes that could explain such results. After MDPV treatment (1.5 mg·kg-1, twice daily, 7 days), mice were behaviorally tested. Also, we investigated protein changes in various brain regions MDPV induced aggressiveness and anxiety, but also contributed to a faster habituation to the open field. This feature co-occurred with an induction of ΔFosB in the orbitofrontal cortex that was higher than its expression in the ventral striatum. Early after treatment, D2R:D1R ratio pointed to a preponderance of D1R but, upon withdrawal, the ratio recovered. Increased expression of Arc, CDK5 and TH, and decrease in DAT protein levels persisted longer after withdrawal, pointing to a neuroplastic lasting effect similar to that involved in cocaine addiction. The implication of the hyperdopaminergic condition in the MDPV-induced aggressiveness cannot be ruled out. We also found an initial oxidative effect of MDPV, without glial activation. Moreover, although initially the dopaminergic signal induced by MDPV resulted in increased ΔFosB, we did not observe any change in NFκB or GluA2 expression. Finally, the changes observed after MDPV treatment could not be explained according to the autoregulatory loop between ΔFosB and the epigenetic repressor G9a described for cocaine. This provides new knowledge about the neuroadaptive changes involved in the vulnerability to psychostimulant addiction.
-Cocaïna
-Dopamina
-Amfetamines
-Ratolins
-Drogues de disseny
-Cocaine
-Dopamine
-Amphetamines
-Mice
-Designer drugs
cc-by-nc-nd (c) Elsevier Ltd, 2018
http://creativecommons.org/licenses/by-nc-nd/3.0/es
Article
Article - Accepted version
Elsevier Ltd
         

Show full item record

Related documents

Other documents of the same author

López Arnau, Raúl; Martínez-Clemente, J.; Pubill Sánchez, David; Escubedo Rafa, Elena; Camarasa García, Jordi
Rubio, Mar; López Arnau, Raúl; Pubill Sánchez, David; Escubedo Rafa, Elena; Camarasa García, Jordi
Pubill Sánchez, David; Ciudad Roberts, Andrés; Duart Castells, Leticia; Ciudad i Gómez, Carlos Julián; Camarasa García, Jordi; Escubedo Rafa, Elena
López-Arnau, Raúl; Buenrostro-Jáuregui, M.; Muñoz-Villegas, P.; Rodríguez-Morató, J.; Ciudad-Roberts, A.; Duart Castells, Leticia; Camarasa García, Jordi; De la Torre, R.; Pubill Sánchez, David; Escubedo Rafa, Elena
Duart Castells, Leticia; López-Arnau, Raúl; Vizcaíno, Sonia; Camarasa García, Jordi; Pubill Sánchez, David; Escubedo Rafa, Elena
 

Coordination

 

Supporters